Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease November 8, 2024 — 17:45
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation September 14, 2024 — 08:18
ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development July 19, 2024 — 00:00
JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS July 13, 2024 — 06:47
KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells July 9, 2024 — 23:00
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024 June 15, 2024 — 22:30
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 June 11, 2024 — 08:10
EASL Wrap-up Session Highlighted Late-Breaking Clinical Data of First-in-class HBV-specific TCR T Cell Therapy (SCG101) Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma June 7, 2024 — 16:51
BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx June 3, 2024 — 23:37
MGI Tech’s DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest June 3, 2024 — 11:35
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 May 18, 2024 — 05:46
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers May 2, 2024 — 07:01
Inaugural ‘Korea Medical Innovation Research Forum’ regular seminar, a success April 19, 2024 — 21:00
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research April 10, 2024 — 14:05
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories March 1, 2024 — 21:35
Tianlong’s New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024 February 8, 2024 — 21:00
MGI Named a Finalist in the 2024 Edison Awards™ for Innovative DNBSEQ-T20x2* Gene Sequencer February 8, 2024 — 21:00
Blossoming Flowers at the Top of the Biopharmaceutical Tree — Reflections on the Flourishing of Sanyou’s 4C Business February 3, 2024 — 08:00
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU January 29, 2024 — 14:05
Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today January 20, 2024 — 08:00
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT) December 29, 2023 — 07:30
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia December 24, 2023 — 17:53
CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors December 21, 2023 — 01:00
